LAWRENCE, Mass., Oct. 21, 2016 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, today announced that it is
participating in the Partners Healthcare Connected Health Symposium
and Expo today, Friday, October 21, 2016 in Boston, MA. More specifically, NxStage
is showcasing recent data associated with its Nx2me Connected
Health® platform that shows a significantly reduced risk of home
hemodialysis (HHD) attrition with HHD patients using this solution.
Lower risk is particularly pronounced during the patients' first
months performing HHD therapy with the NxStage® System One™.
"As a leader in home dialysis, NxStage has been at the forefront
of connected health with innovative technology that enables
connectivity and supports data sharing between home patients and
their care teams," said Joseph E.
Turk, president of NxStage. "We're excited to be showcasing
our capabilities in this area with Nx2me data that continues to
reaffirm how these innovations help ensure better success at home
for patients."
A key component of the Nx2me platform is the Nx2me iPad® app,
which is designed to increase patients' ease of use of home therapy
by monitoring and capturing treatment data and wirelessly sending
it to their center after each treatment, thereby reducing the need
for paper flow sheets. Dialysis center staff can access the
treatment data using the Nx2me Clinician Portal to review and
follow treatment adherence and progress. Importantly, Nx2me patient
treatment data can be easily integrated into EMR systems.
For more information about Nx2me and HHD with the NxStage System
One, please visit www.NxStage.com.
For more information about the Partners Healthcare Connected
Health Symposium and Expo 2016, please visit
https://symposium.connectedhealth.org/.
* Lower Risk of Home Hemodialysis Attrition in Patients Using
Nx2me Connected Health Technology. J Molina, P Kravitz, E
Weinhandl.
Despite the health benefits that home hemodialysis may provide
to those with chronic kidney disease, this form of therapy is not
for everyone. The reported benefits of home hemodialysis may not be
experienced by all patients. The risks associated with hemodialysis
treatments in any environment include, but are not limited to, high
blood pressure, fluid overload, low blood pressure, heart-related
issues, and vascular access complications. The medical devices used
in hemodialysis therapies may add additional risks including air
entering the bloodstream and blood loss due to clotting or
accidental disconnection of the blood tubing set. Certain risks are
unique to the home. Treatments at home are done without the
presence of medical personnel and on-site technical support.
Patients and their partners must be trained on what to do and how
to get medical or technical help if needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. In
addition, NxStage's Nx2me Connected Health platform
collects important NxStage System One and patient
information for flexible viewing, monitoring and reporting
that may improve patient management and patient retention, as well
as simplify alternative site
care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical,
Inc. (Nasdaq: NXTM) is a leading medical technology
company, headquartered in Lawrence, Massachusetts,
USA, that develops, manufactures
and markets innovative products for the treatment of end-stage
renal disease (ESRD) and acute kidney failure. NxStage also has
established a small number of dialysis clinics committed to the
development of innovative care delivery models for patients with
ESRD. For more information on NxStage and its products and
services, please visit the Company's websites
at www.nxstage.com andwww.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and
Exchange Commission, including its Quarterly Report on Form
10-Q for the quarter ended June 30, 2016. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard,
Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-highlights-innovative-nx2me-platform-data-at-partners-healthcare-connected-health-symposium--expo-2016-300349010.html
SOURCE NxStage Medical, Inc.